Home › Funds › Two Seas Capital LP › ABUS

Two Seas Capital LP position in ABUS

ARBUTUS BIOPHARMA CORP · Health Care

Two Seas Capital LP reported holding 8,143,994 shares of ABUS (ARBUTUS BIOPHARMA CORP) in its Q3 2026 13F filing — a position valued at US$38.9M, representing 0.51% of its reported portfolio and ranking #22 among its reported holdings. Two Seas Capital LP has disclosed ABUS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)8.14M sh
Reported value held$38.93M
Portfolio Weight0.51%
First reportedQ3 2023
Last changeReduce
Updated2026-10-09

Last updated: 2026-10-09 · Source: SEC EDGAR Form 13F-HR

How Two Seas Capital LP's ABUS position evolved

Two Seas Capital LP first disclosed a stake in ABUS in Q3 2023 at 8,280,818 shares (US$16.8M). The position peaked in Q2 2026 at 19,095,583 shares, worth US$91.7M. Across 13 filings, Two Seas Capital LP increased the stake 9 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 8,143,994 shares valued at US$38.9M — a reduction of -10,951,589 shares quarter over quarter.. Notable position changes include a 47% increase in Q1 2026 (shares rose 7% over the following quarter), a 57% trim in Q3 2026 (shares fell 19% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 8.28M $16.81M New
Q4 2023 9.04M $22.60M Add
Q1 2024 7.84M $20.23M Reduce
Q2 2024 8.57M $26.49M Add
Q3 2024 8.39M $32.29M Reduce
Q4 2024 8.74M $28.58M Add
Q1 2025 9.47M $33.04M Add
Q2 2025 10.44M $32.27M Add
Q3 2025 10.99M $49.90M Add
Q4 2025 12.59M $60.55M Add
Q1 2026 18.56M $83.51M Add
Q2 2026 19.10M $91.66M Add
Q3 2026 8.14M $38.93M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABUS and 13F data

ABUS (ARBUTUS BIOPHARMA CORP) is a Health Care company. 43 other funds we track also report a position in ABUS — the largest reported positions include Whitefort Capital Management, LP (US$75.8M), BlackBarn Capital Partners LP (US$12.0M), Deltroit Asset Management (UK) LLP (US$5.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABUS

All ABUS fund holders →

FAQ

How long has Two Seas Capital LP held ABUS?

Two Seas Capital LP has disclosed ABUS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Two Seas Capital LP's current position in ABUS?

As of Q3 2026, Two Seas Capital LP holds 8.14M shares of ABUS (ARBUTUS BIOPHARMA CORP), valued at $38.93M, representing 0.51% of its reported portfolio and ranking #22.

Has Two Seas Capital LP been buying or selling ABUS?

In the latest 13F filing (Q3 2026), Two Seas Capital LP reduced its position in ABUS. The position peaked in Q2 2026 at 19.10M shares.

Which other funds hold ABUS?

Other major institutional holders of ABUS include Whitefort Capital Management, LP, BlackBarn Capital Partners LP, Deltroit Asset Management (UK) LLP, among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.